GALT · XBRL financial data

Galectin Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (GALT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	17,976	23,818	31,737	32,130	36,571	14,290
General and administrative	5,468	6,361	6,615	5,942	5,862	5,795
Total operating expenses	23,444	30,179	38,352	38,072	42,433	20,085
Operating income (loss)	(23,444)	(30,179)	(38,352)	(38,072)	(42,433)	(20,085)
Interest income	66	3	52	230	338	126
Interest expense	87	489	1,033	2,792	5,540	7,329
Income tax expense (benefit)	—	—	—	—	0	0
Net income (loss)	(23,465)	(30,527)	(38,776)	(41,066)	(47,047)	(30,836)
Earnings per share, basic USD per share	(0.41)	(0.52)	(0.65)	(0.74)	(0.76)	(0.48)
Earnings per share, diluted USD per share	(0.41)	(0.52)	(0.65)	(0.74)	(0.76)	(0.48)
Weighted average shares, basic thousands of shares	57,029	58,527	59,391	60,159	62,309	63,903
Weighted average shares, diluted thousands of shares	57,029	58,527	59,391	60,159	62,309	63,903

Fiscal years (GALT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	27,142	39,648	18,592	25,660	15,120	17,720
Prepaid and other current assets	2,323	2,172	1,960	2,050	2,132	1,716
Total current assets	29,465	41,820	20,552	27,710	17,252	19,436
Property and equipment, net	0	0	0	0	0	0
Right-of-use asset	—	7	86	53	16	22
Total assets	29,600	41,827	21,285	28,200	17,495	19,532
Accounts payable	1,292	1,805	3,890	6,431	5,656	3,245
Accrued liabilities	4,042	7,163	9,058	9,182	8,204	4,722
Total current liabilities	5,399	9,033	13,012	15,676	35,409	8,030
Lease liability, non-current	—	—	66	20	—	—
Total liabilities	5,407	39,211	53,479	88,441	120,565	145,727
Accumulated deficit	(239,996)	(270,694)	(309,567)	(354,372)	(401,572)	(432,546)
Total stockholders' equity	22,470	893	(33,917)	(61,964)	(104,793)	(127,918)
Total liabilities and equity	29,600	41,827	21,285	28,200	17,495	19,532
Common shares outstanding (cover page) thousands of shares	57,156	59,358	59,444	61,904	63,180	65,827

Fiscal years (GALT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(23,465)	(30,527)	(38,776)	(41,066)	(47,047)	(30,836)
Stock-based compensation	1,799	2,076	2,867	2,261	2,447	1,659
Net cash from operating activities	(20,601)	(24,308)	(31,056)	(32,965)	(41,767)	(23,875)
Net cash from investing activities	0	0	0	0	0	0
Proceeds from issuing common stock	263	6,814	0	—	0	3,235
Net cash from financing activities	263	36,814	10,000	40,033	31,227	26,475

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Galectin Therapeutics	13,269	not reported	(2,439)*	100.8M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Cartesian Therapeutics	147,606	0	(21,082)*	30.3M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Enanta Pharmaceuticals	33,419	14,359	(9,972)*	29.1M	19.0 quarters	Q3 FY26 10-QJun 30, 2026
Atossa Therapeutics	26,094	not reported	(9,644)*	10.0M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
TuHURA Biosciences	996	not reported	(8,634)*	63.7M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Fennec Pharmaceuticals	41,249	17,874	50*	35.1M	—	Q2 FY26 10-QJun 30, 2026
Protara Therapeutics	17,076	not reported	(15,389)*	59.1M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
Caribou Biosciences	26,194	1,499	(22,787)*	107.2M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Fate Therapeutics	32,429	2,082	(23,400)	119.8M	6.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.